American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Long-Term Outcomes of Ibrutinib Therapy in CLL

ASH 2023 - CLL

Long-term follow-up data of a phase 2 study confirmed the extended prognosis of ibrutinib-treated patients with CLL, particularly those with TP53 alterations. Read More ›

Extended Follow-up of ALPINE Study Confirmed Superior PFS Benefit of Zanubrutinib Versus Ibrutinib in R/R CLL/SLL

ASH 2023 - CLL

Longer follow-up data of the randomized, phase 3 ALPINE study confirmed PFS benefit and more favorable cardiac safety profile of zanubrutinib compared to ibrutinib therapy in patients with R/R CLL/SLL, with emergence of no new safety signals. Read More ›

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/Refractory CLL

ASH 2023 - CLL

Results of the phase 2 CLL2-BAAG trial showed that MRD-guided triple combination therapy of acalabrutinib, venetoclax and obinutuzumab yielded better efficacy outcomes, deeper remission, and achievement of uMRD in patients with R/R CLL. Read More ›

Phase 1/2 Study Data of Combination Sonrotoclax (BGB-11417) Plus Zanubrutinib in Treatment-Naïve CLL/SLL

ASH 2023 - CLL

Data from an ongoing, first-in-human phase 1/2 study suggests that combination sonrotoclax (160 mg and 320 mg) plus zanubrutinib therapy was well tolerated and showed encouraging anti-leukemic activity in patients with treatment-naive CLL/SLL. Read More ›

Patients with Advanced Myelofibrosis Receiving Bomedemstat Exhibit Improved Clinical Outcomes Compared to JAK Inhibitors

ASH 2021 - Myelofibrosis

Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib. Read More ›

TGFβ-Regulated Progression of Thrombocytopenia Reduced in Patients with Advanced Myelofibrosis Receiving AVID200 Therapy

ASH 2021 - Myelofibrosis

TGFβ is a cytokine that enhances myelofibrosis disease progression. AVID200, a TGFβ1/3 inhibitor, may provide clinical benefit manifesting as improved platelet counts in patients with myelofibrosis who have thrombocytopenia. Read More ›

Tagraxofusp Monotherapy Demonstrated Clinical Efficacy in Patients with Advanced Myelofibrosis and Refractory to JAK Inhibitor Therapy

ASH 2021 - Myelofibrosis

JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data. Read More ›

Association Between IPSS Score and JAK Mutation Characterize Patients with Myelofibrosis at High Risk for Thrombosis

ASH 2021 - Myelofibrosis

Thrombus formation in patients with myelofibrosis is a common marker of disease progression. The relationship between IPSS score and JAK mutation status may distinguish patients at high risk for thrombosis, which may serve as a guide to therapy decisions. Read More ›

Analysis of Patients with Essential Thrombocythemia or Myelofibrosis Enrolled in Clinical Trials in Academic versus Community Centers

ASH 2021 - Myelofibrosis

Patients with essential thrombocythemia and myelofibrosis enroll in various studies in both academic and community centers across the United States. The comparison of patient characteristics across these centers may provide valuable insight into the management of these myeloproliferative neoplasms. Read More ›

Fludarabine-Busulfan Conditioning Demonstrates Improved Outcomes in Patients with Myelofibrosis After Allo-HSCT

ASH 2021 - Myelofibrosis

Conditioning regimens for allo-HSCT includes either myeloablative conditioning or reduced-intensity conditioning. The use of fludarabine/busulfan appears to deliver better patient outcomes after transplant compared with other commonly used conditioning regimens. Read More ›

American Society of Hematology (ASH)

Page 2 of 44